Inhibitor Therapeutics Inc
Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal… Read more
Inhibitor Therapeutics Inc (INTI) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -220.459x
Based on the latest financial reports, Inhibitor Therapeutics Inc (INTI) has a cash flow conversion efficiency ratio of -220.459x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-761.25K) by net assets ($3.45K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Inhibitor Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Inhibitor Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Inhibitor Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Inhibitor Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
DARI COUSPATE
BC:DARI-COUSPATE
|
N/A |
|
SUNMIRROR AG SF 1
F:ROR
|
N/A |
|
Mint Incorporation Limited Class A Ordinary Shares
NASDAQ:MIMI
|
N/A |
|
RNI Negócios Imobiliários S.A
SA:RDNI3
|
-0.026x |
|
Merida Minerals Inc.
V:ESPN
|
0.000x |
|
Aakash Exploration Services Limited
NSE:AAKASH
|
0.010x |
|
Planet Ventures Inc
PINK:PNXPF
|
0.003x |
|
ALX Resources Corp
PINK:ALXEF
|
-0.028x |
Annual Cash Flow Conversion Efficiency for Inhibitor Therapeutics Inc (2015–2024)
The table below shows the annual cash flow conversion efficiency of Inhibitor Therapeutics Inc from 2015 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.99 Million | $-3.23 Million | -1.629x | -218.71% |
| 2023-12-31 | $5.28 Million | $-2.70 Million | -0.511x | -136.11% |
| 2022-12-31 | $8.30 Million | $11.74 Million | 1.415x | +2224.54% |
| 2021-12-31 | $-3.62 Million | $-220.43K | 0.061x | -75.21% |
| 2020-12-31 | $-3.36 Million | $-825.36K | 0.246x | -77.02% |
| 2019-12-31 | $-2.53 Million | $-2.71 Million | 1.069x | +100.93% |
| 2018-12-31 | $32.35K | $-3.71 Million | -114.626x | -555.40% |
| 2017-12-31 | $166.56K | $-2.91 Million | -17.489x | -3171.20% |
| 2016-12-31 | $7.03 Million | $-3.76 Million | -0.535x | +89.99% |
| 2015-12-31 | $423.98K | $-2.26 Million | -5.339x | -- |